SIGA - SIGA Technologies, Inc.
8.13 0.00 (0.00%)
After hours: 4:44PM EDT
| Previous Close | 7.91 |
| Open | 7.95 |
| Bid | 7.92 x 1100 |
| Ask | 8.50 x 1000 |
| Day's Range | 7.92 - 8.28 |
| 52 Week Range | 2.85 - 8.28 |
| Volume | 199,692 |
| Avg. Volume | 419,012 |
| Market Cap | 643.572M |
| Beta | 0.04 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.50 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.00 |
- Benzinga•29 days ago
Siga Continues Rally After FDA Approves Smallpox Drug
Siga Technologies (NASDAQ: SIGA) announced the FDA's approval of TPOXX, or tecovirimat. The drug consists of an antiviral treatment designed to diminish the effects of smallpox upon outbreak and is the first approved treatment of its kind. The smallpox drug's importance is twofold.
- GlobeNewswire•last month
U.S. Food and Drug Administration Approves SIGA Technologies’ TPOXX® (tecovirimat) for the Treatment of Smallpox
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the U.S. Food and Drug Administration (FDA) has approved oral TPOXX® (tecovirimat) for the treatment of smallpox to mitigate the impact of a potential outbreak. TPOXX, a small-molecule antiviral treatment for smallpox, is the first therapy specifically approved for this indication.
- MarketWatch•last month
SIGA Technologies shares rise 10% on approval of first-ever smallpox therapy
SIGA Technologies Inc. (SIGA) rose 9.6% in Friday afternoon trade on the Food and Drug Administration's approval of its TPOXX, the first-ever smallpox therapy. The contagious and often-deadly disease -- described as "one of the world's most devastating diseases known to humanity" by the World Health Organization -- has been considered eradicated since 1980 due to global immunization, but there have been fears that it could be used for bioterrorism, the FDA said. To establish the product's safety, it was tested in 359 healthy humans who did not have smallpox, while the efficacy findings that the approval was based on were in animals.
- GlobeNewswire•last month
Pivotal Trial Data for SIGA Technologies’ Oral TPOXX® Published in the New England Journal of Medicine
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, which comprises countermeasures for biological, chemical, radiological and nuclear attacks as well as vaccines and therapies for emerging infectious diseases and health preparedness to address serious unmet medical needs, today announced the publication of data in the New England Journal of Medicine from its pivotal human safety and animal efficacy studies of its oral formulation of TPOXX® (tecovirimat). These results support the antiviral activity and favorable safety profile of TPOXX for the treatment of smallpox. “Smallpox is both highly contagious and highly lethal and there is growing concern that smallpox could be used as a potential bioweapon,” said Phil Gomez, PhD, SIGA’s Chief Executive Officer.
- GlobeNewswire•2 months ago
SIGA to Present at the Jefferies Global Healthcare Conference on June 8, 2018
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, SIGA’s Chief Executive Officer, will present at the Jefferies Global Healthcare Conference at 12:30 pm ET on Friday, June 8, 2018 in New York. Dr. Gomez will provide a corporate update and discuss the company’s lead investigational product TPOXX®, an antiviral drug targeting the treatment of smallpox. SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market.
- Benzinga•3 months ago
Benzinga's Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks ( Stocks hitting 52-week highs on May 2 ) CASI Pharmaceuticals Inc (NASDAQ: CASI ) Eleven Biotherapeutics ...
- Benzinga•3 months ago
Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 1) ABIOMED, Inc. (NASDAQ: ABMD ) AveXis Inc (NASDAQ: AVXS ) (announced ...
- ACCESSWIRE•6 months ago
Emerging Developments: New Research on Siga Technologies and Tropicana Entertainment - A Look Ahead into 2018
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of Siga Technologies Inc. (OTC PINK: SIGA) and Tropicana Entertainment ...
Capital Cube•last yearSIGA Technologies, Inc. :SIGA-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
Categories: Yahoo FinanceGet free summary analysis SIGA Technologies, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of SIGA Technologies, Inc. – Achillion Pharmaceuticals, Inc., Emergent BioSolutions Inc., SciClone Pharmaceuticals, Inc., Novavax, Inc., Sarepta Therapeutics, Inc., Chimerix, Inc., BioCryst Pharmaceuticals, Inc. and Newlink Genetics Corporation (ACHN-US, ... Read more (Read more...)